This site is intended for healthcare professionals
News

China National Medical Products Administration approves tislelizumab to treat metastatic urothelial carcinoma with PD-L1 high expression .- BeiGene Ltd

Read time: 1 mins
Last updated:28th Jun 2021
Published:12th Apr 2020
Condition: Bladder Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest